<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780650</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00044873</org_study_id>
    <nct_id>NCT00780650</nct_id>
  </id_info>
  <brief_title>Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine</brief_title>
  <official_title>Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at determining if the drug Atomoxetine (Strattera-used to treat Attention
      Deficit Hyperactivity Disorder(ADHD) has effects on the body's ability to defend itself
      against low blood sugar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to see if the drug atomoxetine (Strattera) has effects on the
      body's ability to defend itself against low blood sugar. Normally, when blood sugar levels
      drop below normal, the body creates a series of responses, which increase the sugar inside
      the body to bring blood sugar levels back to normal. The hormone epinephrine is a key defense
      against low blood sugar in people with diabetes. Atomoxetine has been shown to increase this
      hormone level. Thus, any approaches to increase levels of this key defense during low blood
      sugar may have great value.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in level of catecholamines in blood from baseline</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>80 mg oral dose, once per day for 6 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>80 mg dose once per day for 6 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals aged 18-50 years

          -  Type 1 Diabetes individuals aged 18-50 years

          -  BMI &lt;40 kg/m2

          -  Females of childbearing potential with negative urine pregnancy test

          -  Volunteers over 40 years of age, a cardiac stress test with no clinically significant
             conduction or ischemic changes

        Exclusion Criteria:

        The following groups of subjects will be excluded from the study:

          -  Pregnant women

          -  Subjects unable to give voluntary informed consent

          -  Subjects on anticoagulant drugs or with known bleeding diatheses

          -  Subjects with uncontrolled hypertension, heart disease, cerebrovascular incidents

          -  Subjects taking MAOIs

          -  Subjects with narrow angle glaucoma

          -  Subjects with diagnosed psychiatric disorders

          -  Subjects with allergy to atomoxetine, heparin, or lidocaine

        Physical Exam Exclusion Criteria:

          -  Uncontrolled severe hypertension (i.e., blood pressure greater than 150/95)

          -  Clinically significant Cardiac Abnormalities (e.g. Heart Failure, Arrhythmias,
             ischemic tachycardia, S-T segment deviations, etc.) from history or from cardiac
             stress testing in subjects &gt; 40 years old.

          -  Pneumonia

          -  Hepatic Failure/Jaundice

          -  Renal Failure

          -  Acute Cerebrovascular/ Neurological deficit

          -  Fever greater than 38.0 C

        Screening Laboratory Tests Exclusion Criteria Blood values as defined in protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N. Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univerisity of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Stephen N. Davis, MBBS</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

